JOHNSON KENNETH ERLAND (See Remarks) received a stock award from XERIS BIOPHARMA HOLDINGS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/1/2023ACC: 0001867096-23-000019
Officer· See Remarks
Since Oct 2021
+100K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
100K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+100K
Price / share
—
Trade value
—
% of position
58.9%
1/31/2023
169.78K→269.78K
Total
Net shares
+100K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/31/2023 | A · Award | +100K | — | — | 58.9% | 169.78K | 269.78K |
| Total | +100K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported